Medrol

Methylprednisolone, the active ingredient in Medrol, is a corticosteroid presented as an oral tablet for oral use. It reduces inflammation and modulates immune responses, and is prescribed for a range of inflammatory and autoimmune conditions in adults and children when indicated by a healthcare professional.

GNH USA supplies Medrol as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for regulated markets. Customers benefit from consistent batch release and comprehensive regulatory documentation.

Methylprednisolone is used to treat inflammatory and immune‑mediated conditions across several organ systems. - Rheumatoid arthritis: reduces joint inflammation and pain, improving mobility. - Asthma exacerbations: decreases airway swelling and improves breathing during acute attacks. - Systemic lupus erythematosus: suppresses immune activity to control disease flares. - Ulcerative colitis: diminishes colon inflammation, aiding symptom relief. - Multiple sclerosis relapse: shortens relapse duration and lessens neurological deficits.

Oral methylprednisolone may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Increased appetite or weight gain. - Mood changes, including irritability or euphoria. - Elevated blood glucose levels. - Gastrointestinal discomfort such as nausea or indigestion.

Serious or Rare Side Effects: - Severe infections or reactivation of latent infections. - Adrenal insufficiency on abrupt discontinuation. - Osteonecrosis of the hip or other bones.

Before initiating therapy, clinicians should evaluate several safety considerations. - Assess infection risk: screen for active or latent infections before use. - Monitor blood glucose: patients with diabetes may need dose adjustments. - Evaluate bone health: long‑term use can decrease bone mineral density. - Review psychiatric history: steroids may exacerbate mood disorders. - Store at ambient temperature: keep tablets below 25 °C in the original container, protected from moisture.

Methylprednisolone can alter the pharmacokinetics or pharmacodynamics of other medicines.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, phenytoin): may reduce steroid efficacy. - Live vaccines: increased risk of disseminated infection.

Moderate Interactions (Monitor Closely): - Anticoagulants (warfarin): may enhance anticoagulant effect, requiring INR monitoring. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): combined use raises gastrointestinal ulcer risk. - Diabetic agents: steroids can raise glucose, necessitating dose review.